I expect most of the cost is regulatory. Lighter regulation around rare "small m... | Hacker News

Hacker Newsnew | past | comments | ask | show | jobs | submit

		BurningFrog on Feb 20, 2022 \| parent \| context \| favorite \| on: First gene therapy for Tay-Sachs disease successfu... I expect most of the cost is regulatory. Lighter regulation around rare "small market" diseases might save a lot of lives. And money.

soldehierro on Feb 20, 2022 [–]

> Lighter regulation around rare "small market" diseases might save a lot of lives. And money.

Orphan drugs for rare diseases are already subject to less regulation.

Guidelines | FAQ | Lists | API | Security | Legal | Apply to YC | Contact